# Tesamorelin Half Life and Pharmacokinetics in the Research Literature > Tesamorelin half life and pharmacokinetics: apparent clearance ~1,060 L/h and a secondary-source terminal half-life of ~26-38 minutes, yet IGF-1 stays elevated across the once-daily interval. Cited. The peptide clears the plasma in minutes; the IGF-1 signal it triggers lasts across the day. That gap is the entire pharmacokinetic story. ## In plain English This page covers tesamorelin half life and pharmacokinetics — that is, how fast the body absorbs, uses, and clears the molecule. Here is the short answer. The peptide itself does not hang around: it is cleared from the blood within minutes. But what it sets in motion lasts much longer. It tells the pituitary to release growth hormone in bursts, and the resulting IGF-1 (a growth signal the liver makes when growth hormone rises) stays elevated across the whole day. So a once-a-day schedule made sense in trials even though the drug is gone from the blood long before then. Think of a single bright lamp lit for a moment that leaves an afterglow. ## Apparent clearance: a brief plasma event A population pharmacokinetic analysis of tesamorelin, dosed at 1-2 mg/day subcutaneously for 14 days in HIV patients and healthy subjects, estimated apparent plasma clearance (CL/F) at approximately 1,060 L/h [8]. That is a high clearance value, and it is the quantitative anchor of the "brief plasma event" picture: the molecule is removed from circulation quickly. The analysis found no clinically relevant demographic covariates affecting the pharmacokinetics — age, sex, and body size did not meaningfully shift the parameters in the studied populations [8]. The same analysis noted one time-dependent change worth flagging: the absorbed fraction was about 13% higher on day 14 than on day 1 [8]. In plain terms, slightly more of each dose appeared to reach the circulation after two weeks of daily dosing than on the first day — a modest accumulation in absorption, not in the peptide itself. ## The ~26-38 minute terminal half-life, attributed correctly Secondary sources — the FDA prescribing label and clinical references such as Mayo Clinic — describe a terminal half-life for tesamorelin on the order of roughly 26-38 minutes. That figure belongs to those secondary sources; the population-PK analysis reports clearance and absorption parameters rather than publishing that specific half-life value [8]. We keep the attribution explicit because precision about provenance is part of reading pharmacokinetics honestly. Whichever number you take, the conclusion is the same: tesamorelin is short-lived in plasma. A terminal half-life measured in tens of minutes is consistent with the high apparent clearance the population analysis reported [8]. The peptide does its signaling and is gone. ## Why a short half-life still supports once-daily dosing Here is the apparent paradox, and its resolution. If the peptide clears in minutes, why was it studied as a once-daily injection? Because the half-life of the molecule and the duration of its effect are two different clocks. A population PK/PD analysis confirmed that tesamorelin stimulates GH secretion in an episodic — pulsatile — manner, and the model linked subcutaneous exposure to the downstream GH and IGF-1 response [9]. GH is released in bursts, and the IGF-1 those bursts generate is sustained across the day [9]. In the pivotal trial IGF-1 rose 81.0% [1], and in 13 healthy men a two-week course raised IGF-1 by 181 ug/L (P<0.0001) [4]. A separate analysis of those same men confirmed the drug augmented endogenous pulsatile GH release directly [6]. IGF-1 is the slow-moving downstream messenger; it persists long after the peptide has cleared. So the dosing interval tracks the biological signal, not the plasma half-life. The lamp is brief; the afterglow carries the day. ## Handling and reconstitution in the studied product ### How is tesamorelin reconstituted in the studied product? In the approved product, tesamorelin is supplied as a lyophilized (freeze-dried) powder that is reconstituted before subcutaneous injection, per the FDA labeling. Research-grade material supplied for laboratory use is not the finished drug product, so this is a description of the studied handling, not a direction for human use. ### Does tesamorelin need to be refrigerated? The FDA label specifies refrigerated storage and use of the reconstituted solution within a defined window. The trans-3-hexenoic acid modification stabilizes the molecule against DPP-IV in the body, but the lyophilized product still has handling requirements drawn from the labeling. These are storage notes from the prescribing information, not self-administration instructions. ### How long does tesamorelin stay in your system? The peptide clears the plasma rapidly — a terminal half-life of roughly 26-38 minutes by secondary sources — but its biological signal lasts longer: GH is released in pulses and the resulting IGF-1 rise is sustained across the day, modeled as episodic GH secretion in the PK/PD analysis [9]. --- One lamp on the tesamorelin record — the minutes-long plasma clearance and the day-long IGF-1 afterglow read straight from the studies and cited to source, with no clinic behind the candle and nothing here dispensed, priced, or sold.